KIMS raises Rs 1,500 crore QIP, cuts long-term debt by Rs 737.4 crore

Krishna Institute of Medical Sciences Limited raised Rs 1,500 crore through a qualified institutions placement, or QIP, and reduced standalone long-term borrowings by Rs 737.4 crore to Rs 365.8 crore as at 30 September 2026. KIMS also received Rs 150 crore upfront from promoter and promoter-group warrants carrying a total issue value of Rs 600 crore.

How much capital did KIMS raise through the QIP?

KIMS raised Rs 1,500 crore through the QIP disclosed in its standalone financial-results notes for the quarter and half year ended 30 September 2026. The company said QIP funds received, net of Rs 24.4 crore of issue expenses, had been used towards the objects stated in the placement document, while the unused amount was temporarily invested in mutual funds and retained in a monitoring account.

The QIP proceeds are reflected in standalone financing cash flow of Rs 1,475.6 crore for proceeds from issue of shares, net of issue expenses, during the half year ended 30 September 2026. This equity inflow contributed to standalone equity rising to Rs 4,213.3 crore at 30 September 2026 from Rs 2,428.7 crore at 31 March 2026, including an increase in share capital to Rs 84 crore from Rs 80 crore.

The balance-sheet change shows that the QIP was accompanied by a larger liquid-investment position rather than an equivalent rise in cash balances. Standalone current investments were Rs 322.4 crore at 30 September 2026, against no current-investment balance shown at 31 March 2026, while cash and cash equivalents declined to Rs 18.3 crore from Rs 25.1 crore over the same dates.

What are the terms of KIMS promoter warrants?

KIMS allotted 77,02,182 convertible warrants to promoters and promoter-group entities on 19 August 2026 at an issue price of Rs 779 per warrant, for an aggregate Rs 600 crore. Each warrant can be converted into one fully paid equity share with a face value of Rs 2, subject to the stated terms and the required exercise by the holder.

The company received Rs 150 crore, or 25% of the issue price, as upfront consideration during the current quarter. The remaining 75%, equal to Rs 450 crore, becomes receivable if warrant holders exercise the warrants. The warrants may be exercised in one or more tranches within 18 months from their allotment date, meaning the filing does not record the unpaid Rs 450 crore as cash received at 30 September 2026.

The Rs 150 crore paid upfront appears in standalone financing cash flow as proceeds from issue of share warrants for the half year ended 30 September 2026. Together, the Rs 1,475.6 crore net share-issue proceeds and the Rs 150 crore warrant proceeds were larger than the Rs 792.9 crore repayment of long-term borrowings in the period, although the filing does not assign individual QIP or warrant proceeds to specific repayments.

How did KIMS reduce standalone borrowings?

KIMS reduced standalone non-current borrowings to Rs 365.8 crore at 30 September 2026 from Rs 1,103.2 crore at 31 March 2026, a reduction of Rs 737.4 crore. Current borrowings also declined, to Rs 267 crore from Rs 349.6 crore, taking total standalone borrowings, excluding lease liabilities, to Rs 632.8 crore from Rs 1,452.8 crore.

Cash-flow data records Rs 792.9 crore of long-term borrowing repayments in the half year ended 30 September 2026, compared with Rs 27.9 crore in the corresponding half year ended 30 September 2025. KIMS also recorded Rs 28.7 crore of proceeds from long-term borrowings, versus Rs 193.9 crore a year earlier, and a Rs 57.2 crore net repayment of short-term borrowings rather than the prior-year net proceeds shown in the filing.

Finance costs were Rs 44.6 crore in the half year ended 30 September 2026, compared with Rs 30.3 crore a year earlier. The higher half-year finance cost sits alongside the materially lower closing borrowings at 30 September 2026, and the filing does not provide a period-end interest-rate explanation for this difference.

Where did KIMS deploy funds during the half year?

KIMS invested Rs 394.5 crore in subsidiaries during the half year ended 30 September 2026, compared with Rs 44.9 crore in the corresponding previous-year period. It also advanced Rs 209.9 crore in loans to subsidiaries and received Rs 119.6 crore in loan repayments, producing a net Rs 90.3 crore outflow through those intercompany loans.

Mutual-fund purchases totalled Rs 1,030.1 crore during the six months to 30 September 2026, while proceeds from mutual-fund sales were Rs 713.4 crore. That represents a net mutual-fund cash deployment of Rs 316.7 crore, consistent with the note that unutilised QIP money was temporarily invested in mutual funds and retained in a monitoring account.

KIMS spent Rs 169.3 crore on property, plant and equipment and other intangible assets, including capital work-in-progress and capital advances, down from Rs 186.8 crore in the half year ended 30 September 2025. Its standalone capital work-in-progress nevertheless rose to Rs 192.5 crore at 30 September 2026 from Rs 116 crore at 31 March 2026, while property, plant and equipment increased to Rs 1,433.6 crore from Rs 1,397.6 crore.

The company also disclosed that, after the current quarter, it acquired 51% of Sarvottam Health Care Private Limited, identified as Trust Multi Speciality Hospital, for cash consideration of Rs 79.5 crore. Because this transaction occurred subsequent to the quarter, it is disclosed as a post-quarter event rather than as a 30 September 2026 standalone balance-sheet item.

Conclusion

KIMS reshaped its standalone funding mix in the half year ended 30 September 2026 through Rs 1,500 crore of QIP fundraising, Rs 150 crore of upfront promoter-warrant receipts and Rs 820 crore of lower total borrowings. The accompanying cash flow shows funding moving into long-term debt repayment, subsidiary investments, loans to subsidiaries, mutual funds and Rs 169.3 crore of capital expenditure.

The next disclosed funding milestone is the possible exercise of the Rs 600 crore promoter and promoter-group warrants allotted on 19 August 2026. KIMS has received Rs 150 crore so far, and the remaining Rs 450 crore is receivable only if holders exercise the warrants, in one or more tranches, within 18 months of allotment.